Perfusion and metabolism imaging studies in Parkinson's disease
- PMID: 22677251
Perfusion and metabolism imaging studies in Parkinson's disease
Abstract
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are important tools in the evaluation of brain blood flow and glucose metabolism in Parkinson's disease (PD). However, conflicting results are reported in the literature depending on the type of imaging data analysis employed. The present review gives a comprehensive summary of the perfusion and metabolism literature in the field of PD research, including quantitative PET studies, normalized PET and SPECT studies, autoradiography studies in animal models of PD, and simulation studies of PD data. It is concluded that PD most likely is characterized by widespread cortical hypometabolism, probably even at early disease stages. Widespread subcortical hypermetabolism is probably not a feature of PD, although certain small basal ganglia structures, such as the external pallidum, may display true hypermetabolism in the absolute sense. This observation is also in agreement with the animal literature.
Similar articles
-
Glucose metabolism in small subcortical structures in Parkinson's disease.Acta Neurol Scand. 2012 May;125(5):303-10. doi: 10.1111/j.1600-0404.2011.01556.x. Epub 2011 Jun 21. Acta Neurol Scand. 2012. PMID: 21692755 Clinical Trial.
-
Subcortical elevation of metabolism in Parkinson's disease--a critical reappraisal in the context of global mean normalization.Neuroimage. 2009 Oct 1;47(4):1514-21. doi: 10.1016/j.neuroimage.2009.05.040. Epub 2009 May 22. Neuroimage. 2009. PMID: 19465133
-
Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages.Brain Struct Funct. 2010 May;214(4):303-17. doi: 10.1007/s00429-010-0246-0. Epub 2010 Apr 2. Brain Struct Funct. 2010. PMID: 20361208 Review.
-
Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease.Neuroimage. 2009 Apr 1;45(2):249-57. doi: 10.1016/j.neuroimage.2008.07.042. Epub 2008 Jul 31. Neuroimage. 2009. PMID: 18718541
-
[18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].Nihon Rinsho. 1997 Jan;55(1):222-6. Nihon Rinsho. 1997. PMID: 9014454 Review. Japanese.
Cited by
-
The Therapeutic Potential of Metformin in Neurodegenerative Diseases.Front Endocrinol (Lausanne). 2018 Jul 19;9:400. doi: 10.3389/fendo.2018.00400. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30072954 Free PMC article. Review.
-
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.Prog Neurobiol. 2017 Oct;157:273-291. doi: 10.1016/j.pneurobio.2015.10.005. Epub 2015 Nov 18. Prog Neurobiol. 2017. PMID: 26603930 Free PMC article. Review.
-
Amygdala Neurodegeneration: A Key Driver of Visual Dysfunction in Parkinson's Disease.Ann Clin Transl Neurol. 2025 Apr;12(4):768-779. doi: 10.1002/acn3.70007. Epub 2025 Feb 17. Ann Clin Transl Neurol. 2025. PMID: 39957584 Free PMC article.
-
Impact of Global Mean Normalization on Regional Glucose Metabolism in the Human Brain.Neural Plast. 2018 Jun 12;2018:6120925. doi: 10.1155/2018/6120925. eCollection 2018. Neural Plast. 2018. PMID: 30008742 Free PMC article.
-
Brain-First versus Gut-First Parkinson's Disease: A Hypothesis.J Parkinsons Dis. 2019;9(s2):S281-S295. doi: 10.3233/JPD-191721. J Parkinsons Dis. 2019. PMID: 31498132 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical